<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7909235</journal-id>
<journal-id journal-id-type="pubmed-jr-id">357</journal-id>
<journal-id journal-id-type="nlm-ta">Brain Dev</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Dev.</journal-id>
<journal-title-group>
<journal-title>Brain &amp; development</journal-title>
</journal-title-group>
<issn pub-type="ppub">0387-7604</issn>
<issn pub-type="epub">1872-7131</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28242040</article-id>
<article-id pub-id-type="pmc">5420478</article-id>
<article-id pub-id-type="doi">10.1016/j.braindev.2017.01.012</article-id>
<article-id pub-id-type="manuscript">NIHMS850824</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>AlOlaby</surname>
<given-names>Reem Rafik</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">**</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sweha</surname>
<given-names>Stefan R</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">**</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silva</surname>
<given-names>Marisol</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Durbin-Johnson</surname>
<given-names>Blythe</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yrigollen</surname>
<given-names>Carolyn M</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pretto</surname>
<given-names>Dalyir</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">*</xref>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Davis, CA, USA</aff>
<aff id="A2"><label>2</label>Department of Biostatistics, University of California Davis, School of Medicine, Davis, CA, USA</aff>
<aff id="A3"><label>3</label>MIND Institute, University of California Davis Medical Center, Davis, CA, USA</aff>
<aff id="A4"><label>4</label>Department of Pediatrics, University of California Davis, School of Medicine, Davis, CA, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding Author: Flora Tassone PhD, Department of Biochemistry and Molecular Medicine, 2805 50th Street, Sacramento, CA 95817, Tel: (916) 703-0463, FAX: (916) 703-0464, <email>ftassone@ucdavis.edu</email></corresp>
<fn fn-type="equal" id="FN2">
<label>**</label>
<p>Both authors contributed equally to this study.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2018</year>
</pub-date>
<volume>39</volume>
<issue>6</issue>
<fpage>483</fpage>
<lpage>492</lpage>
<!--elocation-id from pubmed: 10.1016/j.braindev.2017.01.012-->
<abstract>
<sec id="S1">
<title>Objectives</title>
<p id="P2">Several neurotransmitters involved in brain development are altered in fragile X syndrome (FXS), the most common monogenic cause of autism spectrum disorder (ASD). Serotonin plays a vital role in synaptogenesis and postnatal brain development. Deficits in serotonin synthesis and abnormal neurogenesis were shown in young children with autism, suggesting that treating within the first years of life with a selective serotonin reuptake inhibitor might be the most effective time. In this study we aimed to identify molecular biomarkers involved in the serotonergic pathway that could predict the response to sertraline treatment in young children with FXS.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P3">Genotypes were determined for several genes involved in serotonergic pathway in 51 children with FXS, ages 24 to 68 months. Correlations between genotypes and deviations from baseline in primary and secondary outcome measures were modeled using linear regression models.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P4">A significant association was observed between a BDNF polymorphism and improvements for several clinical measures, including the Clinical Global Impression scale (P= 0.008) and the Cognitive T Score (P= 0.017) in those treated with sertraline compared to those in the placebo group. Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.</p>
</sec>
<sec id="S4">
<title>Conclusion</title>
<p id="P5">This study shows that polymorphisms of genes involved in the serotonergic pathway could play a potential role in predicting response to sertraline treatment in young children with FXS. Larger studies are warranted to confirm these initial findings.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Fragile X Syndrome</kwd>
<kwd>Serotonin</kwd>
<kwd>Sertraline</kwd>
<kwd>Selective Serotonin Reuptake Inhibitor</kwd>
<kwd>BDNF</kwd>
<kwd>Cytochrome P450</kwd>
<kwd>Neurotransmitters</kwd>
<kwd>Molecular Biomarkers</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>